Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus

CHIN-HSIAO TSENG2021-04-292021-04-2920211873-9946https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090064284&doi=10.1093%2fecco-jcc%2fjjaa136&partnerID=40&md5=96568518f6dcf45bace443981269d669https://scholars.lib.ntu.edu.tw/handle/123456789/558309Aim: Our aim was to compare the risk of developing inflammatory bowel disease [IBD] between ever users and never users of metformin. Methods: Patients with newly diagnosed type 2 diabetes mellitus from 1999 to 2005 were enrolled from Taiwan's National HeaCrohn's disease; Inflammatory bowel disease; metformin; Taiwan; ulcerative colitis[SDGs]SDG3acarbose; acetylsalicylic acid; angiotensin receptor antagonist; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; meglitinide; metformin; oral antMetformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitusjournal article10.1093/ecco-jcc/jjaa136326044122-s2.0-85090064284